Mealey's (October 2, 2019, 10:29 AM EDT) -- DENVER — Thirty-eight cancer treatment facilities on Sept. 24 told the 10th Circuit U.S. Court of Appeals that a district court erred in ruling that federal preemption bars their claims that drug maker Genentech Inc. sold them adulterated vials of the chemotherapy drug Herceptin that were underfilled (In Re: MDL 2700 Genentech Herceptin, et al., No. 19-5035, 10th Cir.)....